Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin A David

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
American Journal of Hematology|March 25, 2023
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centersKevin A David, Suchitra Sundaram, Seo-Hyun Kim, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Leukemia & Lymphoma|March 24, 2023
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohortPrashasti Agrawal, Kevin A David, Zhengming Chen, et al.
Blood Advances|October 21, 2022
Postibrutinib relapse outcomes for patients with marginal zone lymphomaNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Blood|September 27, 2021
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutionsVictor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Hematology & Oncology|November 10, 2023
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Lei Feng, Nirav N Shah, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
American Journal of Hematology|March 25, 2023
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centersKevin A David, Suchitra Sundaram, Seo-Hyun Kim, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Leukemia & Lymphoma|March 24, 2023
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohortPrashasti Agrawal, Kevin A David, Zhengming Chen, et al.
Blood Advances|October 21, 2022
Postibrutinib relapse outcomes for patients with marginal zone lymphomaNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Blood|September 27, 2021
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutionsVictor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook, et al.
Pageof 4